Montelukast (Singulair) Black Box Warning for Pediatric Psychiatric Patients
The FDA issued a black box warning for montelukast in March 2020 specifically alerting prescribers to serious neuropsychiatric adverse events including agitation, aggressive behavior, depression, sleep disturbances, suicidal thoughts and behavior (including completed suicide), and other mental health symptoms in patients of all ages, including children and adolescents, with or without prior psychiatric history 1.
Key Components of the Warning
The black box warning encompasses the following critical elements:
Reported Neuropsychiatric Events
The FDA documented highly variable postmarketing reports including 1:
- Mood and behavioral changes: Agitation, aggressive behavior or hostility, anxiousness, depression, irritability
- Cognitive disturbances: Disorientation, disturbance in attention, memory impairment
- Sleep-related problems: Insomnia, dream abnormalities, somnambulism (sleepwalking)
- Serious psychiatric events: Suicidal thoughts and behavior (including completed suicide), hallucinations
- Other symptoms: Obsessive-compulsive symptoms, restlessness, dysphemia (stuttering), tic, tremor
Critical Clinical Considerations
Timing: Most neuropsychiatric events occurred during active treatment, though some were reported after discontinuation 1.
Risk factors: Events have been documented in pediatric patients both with AND without previous psychiatric history, making it impossible to reliably predict which children are at risk 1.
Mechanism: While animal studies show montelukast distributes into the brain, the underlying mechanisms for these psychiatric effects remain poorly understood 1.
Prescribing Restrictions and Recommendations
For Allergic Rhinitis
Reserve montelukast ONLY for patients with inadequate response or intolerance to alternative therapies 1. The FDA specifically restricted this indication due to the availability of safer alternatives.
For Asthma and Exercise-Induced Bronchoconstriction
Prescribers must carefully weigh benefits versus risks before initiating treatment, particularly when symptoms are mild and alternative therapies are available 1.
Mandatory Monitoring and Patient Education
Before Prescribing
- Discuss benefits and risks explicitly with patients and caregivers 1
- Document this discussion in the medical record
- Obtain informed consent acknowledging the neuropsychiatric risks
During Treatment
Instruct patients and caregivers to be vigilant for 1:
- Changes in behavior
- New neuropsychiatric symptoms
- Suicidal thoughts or behavior
If Symptoms Occur
Immediately discontinue montelukast and contact healthcare provider 1. This is non-negotiable—do not wait to see if symptoms resolve on their own.
Continue monitoring even after discontinuation because symptoms may persist after stopping the medication 1. Provide supportive care until complete resolution.
Clinical Context and Evidence
Real-world data supports the FDA's concerns. A retrospective cohort study found that 16% of asthmatic children discontinued montelukast due to neuropsychiatric adverse events, with a 12-fold higher risk compared to inhaled corticosteroids 2. Most events occurred within 2 weeks of initiation, with irritability, aggressiveness, and sleep disturbances being most common 2.
However, more recent large-scale observational studies present conflicting evidence. A Swedish nationwide study of 74,291 children found no increased risk of neuropsychiatric events with montelukast compared to long-acting beta-agonists (HR 0.99,95% CI 0.84-1.16) 3. This discrepancy highlights the complexity of the issue but does not negate the FDA's regulatory decision based on postmarketing surveillance data.
Common Pitfalls to Avoid
Do not assume prior psychiatric stability predicts safety: The warning explicitly states events occur in patients without psychiatric history 1.
Do not continue montelukast if neuropsychiatric symptoms emerge: The directive is to discontinue immediately, not to "monitor closely" while continuing treatment 1.
Do not assume symptoms will resolve immediately upon discontinuation: Some cases showed persistent symptoms requiring ongoing supportive care 1.
Do not use montelukast as first-line for allergic rhinitis: This is now explicitly contraindicated by the FDA labeling changes 1.
The Austrian working group of pediatric pulmonology and allergology reinforces this cautious approach, recommending that montelukast should only be started after critical evaluation and stopped immediately upon occurrence of any neuropsychiatric side effects 4.